Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: Where the Preclinical Rationale Holds. Translational Medicine & Therapeutics Journal, [S. l.], v. 5, n. 2, p. 28–36, 2026. DOI: 10.5281/zenodo.22649559. Disponível em: https://inkwise.org/index.php/TMTJ/article/view/119. Acesso em: 5 nov. 2026.